Admedes Invests $80 (€56) Million to Expand Nitinol Manufacturing and Develop New Technologies

Spurred by market demand for Nitinol-based medical devices and implants used in cardio-vascular medical applications, Admedes Schuessler GmbH is strategically investing $80 million to expand its Nitinol manufacturing operations and develop new technologies to support the medical device industry’s rapid pace of innovation.

Pforzheim, Germany (October 15, 2012) – Spurred by market demand for Nitinol-based medical devices and implants used in cardio-vascular medical applications, Admedes Schuessler GmbH is strategically investing $80 million to expand its Nitinol manufacturing operations and develop new technologies to support the medical device industry’s rapid pace of innovation.

The expansion will include a new building at the Pforzheim, Germany location and will add 195,000ft2 (18,000m2) space for production, labs, offices and space for the new Admedes Innovation Centre. 

Admedes is focusing on increasing the level of automation in serial production lines and expansion of lean manufacturing methods. The investments will effectively double the production area and improve efficiencies of Nitinol manufacturing operations, providing additional flexibilityto support customer’s needs.

“This investment will secure our position as the leading manufacturer of Nitinol implants.   Combined with continued innovation in Admedes’ offerings, we will solidify our competitiveness and attractiveness to our customers,” stated Dr. Andreas Schuessler, founder and CEO. “With the extraordinary quality we deliver, the high flexibility, efficiencies, and economies of scale, we can continue to attract customers who do their Nitinol production in-house. Outsourcing will be made very attractive for them.”

Admedes’ strong reputation as an innovative partner led to the creation of the new Innovation Center, which allows more effective collaboration with customers earlier and throughout the development cycle.  The Innovation Center brings together Admedes expert engineering and scientific teams for the development of new technologies that will enable new applications, materials and design options for implantable medical device companies.

The ground breaking ceremony was held in September 2012 and the grand opening is expected by the end of 2013.  Visit www.admedes.com to learn more about Admedes services and see daily updates on the construction progress.

About Admedes Schuessler GmbH

Admedes Schuessler GmbH is the world’s leading OEM manufacturer of finished Nitinol medical implants and employs over 750 people in its German headquarters and US operations.  The company works in close collaboration with the medical device industry to provide rapid response prototyping, pilot line and serial production of Nitinol based medical device implants and components. The company is committed to ongoing process innovation to enable a superior competitive position in the global marketplace from strategic and high quality manufacturing locations as well as in the development of new technologies and capabilities to enable innovative options and solutions for medical device company’s development of novel therapeutic devices.

Admedes quality systems are both ISO 13485/9001 certified and FDA 21 CFR Part 820 registered contract manufacturer.